Pfizer’s PR Review in Final Stages

BOSTON Pfizer’s search for an agency holding company to handle public relations duties for its cardiovascular drug treatment franchise is in the final stages.

In November, the New York-based client invited WPP, Interpublic Group and Omnicom to each assemble public relations teams to pitch the account. Since then, Omnicom has dropped out of the competition. The reason for that departure is undisclosed.

Pfizer has begun hearing pitches, and a decision will be made by the end of January, according to a company representative. Billings for the account are undisclosed.

The pharmaceutical giant’s cardiovascular drug line includes the cholesterol-lowering Lipitor as well as Norvasc and Caduet.